Associated equity: BB Biotech
BB Biotech, a Swiss-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.
BB Biotech — 9 videos in collection
BB Biotech is managed by Bellevue Asset Management, a Swiss-based asset manager specialising in healthcare investments. BB Biotech offers investors access to the dynamic biotechnology sector, aiming for long-term capital growth by investing in cutting-edge companies developing transformative therapies.
We highlight the key points of BB Biotech’s investment story.
1. BB Biotech provides investors with access to an exciting, rapidly growing industry.
2. BB Biotech is a leading investor in the biotech sector.
3. The company is focused on commercial-stage investments.
4. The outlook for the biotech sector is bright.
If you would like to find out more about BB Biotech, please see our latest research.